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Abstract
Androgen receptor mediated signaling drives prostate cancer cell growth and survival. Mutations within the receptor occur
infrequently in prostate cancer prior to hormonal therapy but become prevalent in incurable androgen independent and
metastatic tumors. Despite the determining role played by the androgen receptor in all stages of prostate cancer
progression, there is a conspicuous dearth of comparable data on the consequences of mutations. In order to remedy this
omission, we have combined an expansive study of forty five mutations which are predominantly associated with high
Gleason scores and metastatic tumors, and span the entire length of the receptor, with a literature review of the mutations
under investigation. We report the discovery of a novel prevalent class of androgen receptor mutation that possesses loss of
function at low levels of androgen yet transforms to a gain of function at physiological levels. Importantly, mutations
introducing constitutive gain of function are uncommon, with the majority of mutations leading to either loss of function or
no significant change from wild-type activity. Therefore, the widely accepted supposition that androgen receptor mutations
in prostate cancer result in gain of function is appealing, but mistaken. In addition, the transcriptional outcome of some
mutations is dependent upon the androgen receptor responsive element. We discuss the consequences of these findings
and the role of androgen receptor mutations for prostate cancer progression and current treatment options.
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Introduction
Globally, prostate cancer (PCa) is the second most frequently
diagnosed cancer of men [1] with the most recent figures from
2010 showing annual deaths of 10,168 in the UK [2] and 32,050
deaths in the US [3] reflecting its prominence as the second
leading cause of cancer death in men in Western nations.
Androgen signaling, which is mediated through the androgen
receptor (AR), directs development, differentiation and carcino-
genesis of the prostate gland [4,5]. Within prostate tumors,
androgen signaling subsequently plays a central role in cancer cell
growth and survival [6,7]. Therefore, androgen ablation through
blocking testicular production of androgens, and inhibition of AR
function with antagonists constitute the principal systemic
treatments for metastatic disease [5,6,8]. Although initially
efficacious, such therapies fail to provide a lasting cure and the
tumor invariably escapes with progression to an exoteric-androgen
independent (AI) state [9] which almost invariably leads to death.
Hormone refractory tumors continue to express functional AR
which plays a critical role in AI cells [10,11] where it drives a
different transcriptome compared to androgen-sensitive cells [12].
The AR, like other members of the steroid hormone receptor
family, is a ligand-activated transcription factor which has distinct
structural and functional domains [13]: the N-terminal domain
(NTD) important for transactivation; the DNA binding domain
(DBD) and the C-terminal ligand binding domain (LBD). Upon
ligand binding, the AR undergoes conformational transformation
facilitating intra- and intermolecular interactions [14]. The transac-
tivational capability of the AR is modulated by several signaling
systems [15] through a range of post-translational modifications
[13,16]. Although the AR exerts most of its actions by functioning as
a transcription factor binding to specific response elements, non-
genomic effects can also contribute to the regulatory outcome.
Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling
pathway not only regulates AR activity through phosphorylation of
the receptor, but also has a major role in the process leading to
invasion and metastasis of PCa cells through downstream phos-
phorylation of affiliated substrates leading to protection from
apoptosis and increased cell survival. The AR can stimulate
PI3K/Akt signaling by interacting directly with the p85a regulatory
subunit of PI3K in response to synthetic and natural androgens [17]
through its NTD [18], and by binding and stimulating Akt1 within
lipid rafts [19]. Many different processes are involved in the
acquisition of hormone resistance [20] and they follow several
diverse routes. Activation of sufficient levels of AR in a castration
environment can occur through missense mutations within the AR
[21], or splice variants, which result in: enhanced binding of
androgens; creation of a constitutively active receptor [22–25];
promiscuous binding of other ligands [26–30] or altered recruitment
of co-activators and co-repressors to the NTD and LBD. The levels
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turnover and gene amplification [31–33]. In addition, aberrant
intratumoral androgen synthesis can lead to activation of AR [34].
Conventional wisdom holds that AR mutations are rare in the
early phases of prostate cancer [35,36] and prevalent in AI and
metastatic tumors [37,38]. In a recent summary of 27 studies, AR
mutations in ‘hormone sensitive’ tumors typically ranged from 2 to
25%, while in ‘hormone refractory’ disease the incidence was 10 to
40% [16]. Because the AR gene is located on the X chromosome,
its hemizygous state in males means that mutations have a direct
phenotypic manifestation. Previous studies on AR mutations have
either simply reported the presence of specific mutations in
prostate cancer biopsies or analyzed a select few examples using
incompatible methodology, thus precluding meaningful compar-
ison of the consequences of the mutations. Given the crucial
importance of AR in all stages of prostate cancer progression and
the paucity of data on the outcomes of mutations, we have
undertaken a comprehensive study of 45 mutations which span the
entire length of the protein and are predominantly associated with
high Gleason scores and metastatic tumors.
Our analysis of the impact of the point mutations on the
receptor’s transactivational activity using a cell culture model
system revealed several significant findings. We report the
discovery of a novel prevalent class of AR mutation that possesses
loss of function at low levels of androgen which transforms to a
gain of function at physiological levels. Mutations leading to
constitutive gain of function are uncommon, whilst the majority of
mutations result in either loss of function or no significant change
from wild-type (WT) activity. Therefore, the widely held opinion
that AR mutations in androgen insensitivity syndrome (AIS) and in
prostate cancer result in loss and gain of function respectively is at
best an over simplification. Furthermore, the transcriptional
outcome of certain mutations is contingent on the AR-responsive
element. Together with a literature review of the mutations under
investigation, this wide-ranging study aims to bolster research into
elucidating the physical basis of the effect of mutations on AR
function and understanding the consequences for patient responses
to androgen ablation therapies.
Results and Discussion
Androgen receptor mutations under study
Inspection of the Androgen Receptor Gene Mutations Database
(http://androgendb.mcgill.ca) [39] and the literature reveals that
prostate cancer-associated single missense mutations occur in the
different domains of the AR with relatively comparable frequen-
cies. Within the NTD, DBD, hinge and LBD, 10, 11, 12 and 15%
of the residues respectively are currently reported to be mutated
(Fig. 1A). The investigation reported here has focused on 45 single
missense mutations detected in PCa with metastasis or high
Gleason scores, and which extend along the entire length of the
protein thereby encompassing all of the different functional
domains. The evolutionary conservation of specific residues was
also employed as a criterion in the selection of mutations (Fig. 1
and Table 1).
The AR, along with the five other related steroid hormone
receptors, originated from successive duplications of an ancestral
steroid receptor gene followed by slow sequence divergence in land
vertebrates [40]. While this has led to high overall homology
between land animals e.g. pig, mouse, chicken and Xenopus AR
share 93, 89, 70 and 85% similarity with human respectively [41],
functional selection has resulted in the different AR domains
exhibiting varying degrees of protein sequence homology between
species.
The NTD is by far the least conserved domain with mouse,
chicken and Xenopus having only 75, 32 and 34% similarity to
human respectively [42]. Alignment of the investigated human AR
mutations to the primary sequence of AR in the representative
species of mouse, pig, chicken and Xenopus (Fig. 1B) shows that,
despite the low sequence identity in the NTD, the vast majority of
the studied residues mutated in PCa have been conserved; even
when the surrounding motif has not. Only two mutated residues
are found in human alone (S296 and D528) and just two are
confined to mammals (S334 and P533). Examples of PCa-related
residues located within highly conserved motifs include A234,
P390, P540, while P269, P340, P514, P515, M523 G524 and
M537 which are present in at least four species, though the motif is
less conserved in more distantly related chicken or Xenopus.
Within the NTD, the region between approximately residues 55
and 230 displays particularly low homology between species,
especially in the examples of bird and amphibian shown here.
Therefore, in this region we have chosen to examine examples of
amino acids implicated in PCa which are present in three or four
species as this would suggest a possible role in the mechanics of AR
function: namely L57, G142, G166, E198 and D221.
Unsurprisingly, the DBD is virtually unaltered across a wide
range of species with 100% homology between the examples
shown here; except for two conservative substitutions in Xenopus,
one of which T575, has been included in the study. The adjacent
hinge region is increasingly viewed as a functionally distinct
domain of the AR rather than merely linking the DBD and LBD
(see Haelens et al [43]). This region (residues 624 to 676) shows
considerably more divergence than its neighbouring domains with
mouse, pig, chicken and Xenopus possessing 85, 94, 38 and 59%
homology to human respectively. The two highly conserved amino
acids R629 and I672 were selected. As the principal function of the
LBD is to bind androgen, it is understandably highly conserved
with pig, mouse, chicken and Xenopus sharing 98, 100, 92 and
88% homology with human. Accordingly, a series of mutations
covering the whole LBD were analyzed.
The sources of the mutations under investigation are shown in
Table 1 and the references describing the identification of most are
listed in the Androgen Receptor Gene Mutations Database
(http://androgendb.mcgill.ca). No mutation was reported to have
come from a germ-line source.
Comparison of reporter plasmids
Initial experiments were performed to determine the most
informative firefly luciferase reporter plasmid with which to
investigate the functional effects of AR mutations on transactivation
activity in the presence of the natural androgen DHT. Comparison
of AR transactivation activity on simple or complex promoters
present in the plasmids GRE2-TATA-Luc, PSA61Luc and MMTV-
Luc, co-transfected into COS-7 cells along with a full length human
AR expression, revealed that all responded to 10 nM DHT;
generating 63.6, 24.3 and 2.6 fold stimulation respectively (Fig. 2A).
The low fold increase in stimulation of MMTV-Luc was due to
very high basal luciferase expression in untreated cells which was
5.2 times greater than for GRE2-TATA-Luc. This was most likely
a consequence of the multiple regulatory elements within the
MMTV-LTR and also possibly due to the fact that AR can
transactivate the MMTV-LTR without androgen-induced NTD/
LBD interaction [44,45]. Comparable low levels of MMTV-Luc
transactivation by androgens have been reported in both non-
prostatic cells e.g. COS-1 [46,47] and PCa cell lines. Within
prostate cells, high basal activity and upregulation of between 2
and 9 fold have been observed with DU145 [48,53], PC-3
[45,48,49], CWR-R1 [50] and LNCaP [47]. Oddly, CV-1 African
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and the most commonly cited cell line for investigating AR
transactivational potentials, routinely exhibit androgen stimulation
of MMTV-Luc in the range of 50 to 120 fold [28,38,51].
In contrast to MMTV-luciferase, PSA61Luc basal activity was
only 0.4 times that of GRE2-TATA-Luc and in the presence of 0.1
and 1.0 nM DHT had zero and 1.4 fold upregulation respectively.
Plasmid PSA61Luc has been reported to have low responses in the
range of 1.4 to approximately 10 fold androgen-stimulation in
COS cells [47,48] and in several PCa cell lines: PC-3 [49,52];
DU145 [53]; 22RW1 [54]; while LNCaP generally show higher
induction of between 40 and 60 fold [55].
Together, COS-7 cells displayed similar characteristics to PCa
cell lines and the presence of the large T antigen does not
adversely influence AR signaling. Of the three plasmids, only
GRE2-TATA-Luc responded to low concentrations of DHT with
2.1 and 24.9 fold stimulation at 0.1 and 1.0 nM DHT respectively.
As knowledge of the behaviour of the mutant ARs in low androgen
concentrations present in castration environments is of major
importance, coupled with the robust stimulation at physiological
concentrations, GRE2-TATA-Luc was selected for comparative
analysis of PCa AR mutations.
A panel of expression plasmids was created encoding wild type
(WT) AR or each of the 45 PCa-associated mutations by in situ
mutagenesis. The integrity of the mutations was confirmed by
DNA sequencing, and the resulting proteins were validated by
western blot analysis; a representative blot is shown in Fig. 2B. The
AR mutation expression plasmids were cotransfected with reporter
plasmid into COS-7 cells which were confirmed not to express AR
(Fig. 2B).
Effects of mutations on AR signaling
Overview. Analysis of the impact of the 45 point mutations
on the androgen receptor’s transactivational activity using our
sensitive cell culture model system are summarized in Fig. 3 and
reveal several significant findings. Assaying transactivation by AR
across a range of DHT concentrations brought to light a
predominant novel class of mutations which had loss of function
at low levels or in the absence of DHT changing to WT values or a
gain of function upon binding of DHT. In addition, the mutations
fell into several groups with distinct characteristics. In order to
facilitate classification of the mutations, an arbitrary value of 10%
difference from WT at two or more hormone concentrations was
set as the level for significant dissimilarity. The mutation groups
are: 1, no significant difference from WT; 2, loss of function at
most or all concentrations of DHT; 3, no significant difference
from WT at low levels or in the absence of DHT with a gain of
function upon binding of DHT; 4, loss of function at low levels or
Figure 1. Mutations under investigation. A. Schematic representation of the hAR protein showing the domain-wide distribution of PCa-related
point mutations and those forming the basis of the study. B. Androgen receptor homology between human and representative species was
determined using ClustalW [96]. The human PCa mutations under study, along with the equivalent residues in other species, are denoted by bold
underlined font.
doi:10.1371/journal.pone.0032514.g001
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function upon binding of DHT; and 5, a constitutive gain of
function defined as transactivation activity in the absence of
hormone.
Unexpectedly, the majority of mutations (28 out of 45, 62%) led
to a loss of function at all concentrations of DHT or were similar
to WT; with very few mutations giving rise to constitutive (7 out of
45, 16%) or dramatic gains of function. Significantly, although loss
of function mutations were predominantly localized to substitu-
tions in the LBD (14 out of 23 mutations, 61%), the different
classes of mutations were distributed along the entire length of the
AR protein.
NTD mutations. All five classes of mutation were repre-
sented within the NTD. Of the five mutations in AR classified as
having no change from WT, G166S showed the least variance
from the unmutated receptor. The mutation M537R also had
minor variation from WT, except at 0.1 nM DHT where 23%
gain of function was seen which could have implications in a low
androgen environment.
The predominant type of mutation i.e. loss of function, was well
represented in the NTD. Mutations L57Q, E198G, D221H,
A234T, S296R; S334P, P340L, P504L and D528G all displayed
loss of function with E198G showing the greatest reduction (50%
at 1 nM) and P340L also being present in AIS. The loss of
transactivational ability was generally seen in both basal activity
and across a wide range of DHT concentrations. A possible
explanation for the loss of function of mutation A234T is that it is
located at the start of the highly conserved motif (residues 234 to
247 [56]) immediately carboxyl-terminal of TAU-1 which forms
the interaction site for the Hsp70-interacting protein E3 ligase
CHIP [57].
Interestingly, there was exiguous rescue at the highest concen-
tration of DHT with D221H, P504L and D528G, while P340L
manifested a striking dose-dependent recovery. The S296R
mutation has been shown to have altered interaction with the co-
repressor N-CoR causing reduced transactivational activity [58].
Mutation of either of the PSTLSL motifs located between residues
159–164 and 340–345 impairs binding of RAP74; the large subunit
of TFIIF [59]. Secondary structure simulations for the P340L
mutation predict creation of a new a-helix [60], so an obvious
possible explanation forits loss of function could be reduced binding
with TFIIF. However, there appears to be another dimension to the
consequences of this mutation. The co-activator ART-27 binds to
the AR NTD and increases transcriptional activity in a dose-
dependentmannerleading toAR-mediatedgrowthsuppressionand
differentiation [61]. Using a cell-based assay system, ART-27 has
been reported to raise the transactivational activity of AR with
mutations E198G, P269S and S334P to a similar degree as WT,
whereas P340L has an approximately 50% loss of ART-27
stimulation due to increased, but inappropriate ART-27 binding
[60]. Given that prostate cancer often has negligible levels of ART-
27 expression, and its expression in LNCaP cells inhibits androgen-
mediated cellular proliferation, P340L provides a classic example of
how a loss of function mutation, also present in AIS, can have the
capacity to drive prostate cancer progression through reduced
growth suppression.
The novel class of mutation, namely loss of function at low levels
or in the absence of DHT recovering to WT values or a gain of
Table 1. Type of prostate cancer in which the AR mutations were detected.
Domain Mutation Prostate Cancer Domain Mutation Prostate Cancer
NTD L57Q Advanced tumor Hinge R629Q AI PCa
G142V Gleason 8 AI PCa I672T Advanced tumor
G166S Locally recurrent Gleason 10 PCa LBD K720E Bone metastases
E198G AI bone marrow metastases R726L Gleason 7 AI PCa
D221H Gleason 9 tumor L744F Latent PCa
A234T AI tumor in TRAMP mouse model A748V Latent PCa
P269S Advanced tumor M749I Latent PCa
S296R AI bone marrow metastases N756D AI PCa
S334P AI bone marrow metastases V757A Metastatic PCa
P340L Advanced tumor V757I AI PCa
P390L AI bone marrow metastases S759P Latent PCa
P504L Patients receiving combined androgen blockade Y763C Latent PCa
P514S Gleason 9 AI PCa A765T AI PCa
S515G Patients receiving combined androgen blockade Q798E Advanced tumor
M523V Patients receiving combined androgen blockade H874Y Metastatic PCa
G524D Gleason 7 AI PCa T877A Metastatic PCa
D528G Advanced tumor D879G AI PCa
P533S Gleason 9 tumor M886I Gleason 7 tumor
M537R Patients receiving combined androgen blockade M886V Source not known
M537V Patients receiving combined androgen blockade Q902R Metastatic AI PCa
DBD T575A Metastatic PCa K910R Gleason 10 tumor
A586V Metastatic PCa Q919R Source not known
A587S Metastatic PCa
doi:10.1371/journal.pone.0032514.t001
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Mutations P269S and S515G had WT levels of transactivational
at 10 nM DHT while P390L (next to the TAU-5 sumoylation site
at K386 in the motif IKLE) and P514S acquired 26 and 30% gain
of function at 10 nM DHT respectively which would be sufficient
to have an impact on AR signaling.
The only mutation to function like WT at low DHT and then
gain function compared to WT upon DHT binding was P533S in
the NTD. As with other groupings, mutations leading to
constitutive transactivation activity were present in all domains
of the AR, including four in the NTD. These are G142V, M523V,
G524D and M537V and all show constitutive activity in the
absence of ligand and modest gain of function at all concentrations
of DHT. Mutations M523V and G524D are next to the
sumoylation site VKSE (518–522) in TAU-5 and this post-
translational modification is considered to repress AR transactiva-
tion potential in a promoter-specific manner. As mutation of the
sumoylation sites in the NTD increases transactivation [16], it is
possible that these prostate cancer mutations may illicit their effect
by lessening sumoylation.
DBD and hinge mutations. Within the hinge region,
mutation I672T has been included in the arbitrary classification
of no change from WT due to deviation of less than 10% at 0 and
0.1 nM DHT changing to a 14% gain of function at 10 nM.
Interestingly, it showed a loss of function of 19% at 1 nM, which is
characteristic of many LBD mutations, suggesting that this region
of the hinge adjacent to the LBD allosterically influences ligand
binding. The DBD and adjoining sequence in the hinge yielded 3
loss to gain of function mutations and these had amongst the
greatest gains seen in the AR. The mutations T575A and R629Q
had similar profiles with loss of function at 0 and 0.1 nM DHT
changing to 85 and 83% gain of function at 10 nM concentrations
respectively. A striking gain of function was seen with A586V with
a loss of function at 0 and 0.1 nM DHT being transformed to a
substantial 460% increase in transactivational activity at 10 nM.
Mutation A587S, which flanks the extremely active mutation
A586V in the middle of the a1 linker between the zinc fingers, had
constitutive transactivational activity with modest gains of function
at all levels of DHT (16 to 28%).
LBD mutations. Mutations in the LBD have historically
been considered as the most likely candidates for driving PCa,
therefore, the finding that the majority of mutations under
investigation had no change from WT or loss of function was
unexpected. The former were represented by M886I and K910R
at the C-terminal end of the LBD and both showed only minor
divergence from WT except for distinctive typical losses of
function at 1 nM DHT (42 and 27% respectively). Although
residue M886 is not essential for ligand binding [51], this mutation
has been determined to alter the interaction of the AR with the
common co-activators TIF-2 or CBP and the co-repressor N-CoR
resulting in elevated and reduced transactivation ability
respectively. Taken together, this apparently benign mutation
could have significantly altered activity in prostate cancer.
Within the LBD, all but two loss of function mutations were
clustered between residues 720 and 798. Of these, half had
essentially no transactivational activity at physiological levels of
DHT and comprise of L744F, A748V, M749I, N756D, S759P,
Y763C and A765T. A similar cluster of loss-of-function mutations
was observed in the TRAMP model in castrated mice or animals
treated with antiandrogens [62]. It is of note that amino acids in
this cluster, which comprise of residues in helix 5 (R752, M745
and M749), a b-strand (F764) and helix 7 (M780 and M787) are
directly in contact with hormone. Furthermore, mutation of the
corresponding conserved residues in the glucocorticoid receptor
revealed an allosteric net work connecting the AF2 surface and the
ligand binding pocket [63] suggesting a possible cause for loss of
function. The remaining LBD loss of function mutations can be
divided into two groups with R726L and V757A showing a
modest loss of function at all levels of DHT, and K720E, V757I,
Q798E, M886V and Q902R all having a distinctive greater loss of
function at 1 nM DHT. This reduction was partially overcome at
10 nM, suggesting reduced affinity for ligand which is ameliorated
at higher concentrations. Two of the mutations tested, V757A and
Q798E showed impaired binding to the p160 co-regulatory
proteins NCoA1 and NCoA2 and impaired N/C-terminal domain
interactions (unpublished observations). Six of the LBD loss of
Figure 2. A. Comparison of firefly luciferase reporter plasmids. COS-7
cells were cotransfected with the indicated luciferase reporter plasmid
and pSVARo expressing WT hAR. The cells were treated with DHT and
firefly luciferase activity was determined. The results were calculated as
the fold stimulation of a given reporter plasmid compared to untreated
cells transfected with the same plasmid. Values are means of a
minimum of three independent experiments performed in quadrupli-
cate 6 SEM. B. Western blotting analysis of hAR expressed by mutated
pSVARo plasmids. COS-7 cells were transiently transfected with plasmid
encoding the indicated mutation, and cell lysates were analyzed for
hAR by western blotting. Lysate from untransfected cells (UT) was used
as the control.
doi:10.1371/journal.pone.0032514.g002
Impact of Androgen Receptor Mutations
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32514Impact of Androgen Receptor Mutations
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32514function mutations (L744F, S759P, Y763C, A765T, Q798E and
M886V) are also present in AIS.
Mutations K720E and R726L, which is implicated in a 6-fold
increased risk of prostate cancer [64], reside in a positive cluster in
helix 3 with lysine 720 creating a charged clamp with glutamate
897, and both residues participate in the binding of the FxxLF motif
present in the AR-NTD as well as the LxxLL found in the p160 co-
regulatory proteins [65,66]. Both mutations impaired binding of
NCoA 1, 2 and 3 and disrupted the N/C-terminal interaction as
expected (unpublished observations). Residue N756 may be
involved in AR dimerization (reviewed in Centenera et al. 2008,
[14]) andmutation to aspartateresulted incomplete loss offunction.
Similarly, P766 is also critical for dimerization with at least two
mutations resulting in AIS and the adjacent prostate cancer
mutations studied here, A765T and Y763C, displayed compro-
mised transactivation activity. Residue Q902 in helix 12 forms part
of an H-bonding network with Q738, so it is quite possible that
positively charged arginine in Q902R disrupts this interaction.
The LBD contained two mutations, D879G and Q919R, which
fall within the grouping of loss to gain of function, although
recovery to a modest 19% gain of function and WT levels
respectively took place at only the highest concentration of DHT.
Only two mutations in the LBD, H874Y and T877A, were found
to have constitutive activity and both displayed loss of function
relative to WT at higher levels of DHT. Threonine 877
participates in hydrogen bonding to the D ring of the steroid
ligand and its mutation in T877A brought about by far the
greatest constitutive gain of function with a 625% increase in
activity compared to WT. The mutation has been studied
extensively and also possesses promiscuous ligand binding (see
[26–30]). As this mutated AR is expressed by the one of the most
routinely used prostate cancer cell lines, LNCaP, the undue
influence of the constitutive activity on cell-based experiments
should be borne in mind.
Dependence of hAR mutation effects on the target regu-
latory element. To determine whether the transcriptional
outcomes of mutations in the AR are influenced by the
regulatory element to which the receptor binds, further studies
were performed using the PSA61Luc luciferase reporter plasmid.
The two copies of the glucocorticoid regulatory element (GRE)
present in GRE2-TATA-Luc [67,68] are non-selective for AR
whereasthethree androgenresponseelements(AREs)inPSA61Luc
are AR-specific (Fig. 4). In addition, the PSA (prostate-specific
antigen) promoter driving expression of luciferase in PSA61Luc is a
natural DNA sequence of 6.1 kbp which regulates expression of
PSA through synergistic cooperative interactions between at least
three AREs [48]. Ten representative mutations were assayed for
transactivational activity under exactly the same conditions, with
the exception that 0.1 nM of steroid was not included, due to the
lack of responsiveness of PSA61Luc at this concentration of the
androgen (Fig. 2A). The results are shown in Fig. 5 and include the
corresponding GRE2-TATA-Luc values for direct comparison.
Figure 3. Stimulatory capacity of hAR mutations present in prostate cancer. COS-7 cells were cotransfected with GRE2-TATA-Luc reporter
plasmid and pSVARo encoding the indicated AR mutation. After treatment with DHT, the luciferase activity was determined. The ability of each AR
mutation to upregulate GRE2-TATA-Luc was calculated as the fold stimulation at each concentration of DHT compared to untreated cells expressing
WT AR. The results are presented as the percentage difference between the mutant and WT AR at each concentration of DHT. Therefore, values below
and above zero represent loss and gain of function compared to WT AR respectively. The concentrations of DHT used were: 0; 0.1; 1.0 and 10 nM with
the corresponding values displayed from left to right in all charts Values are means of between three and five independent experiments performed in
quadruplicate 6 SEM. The positions of the mutations are indicated with reference to a schematic representation of the hAR drawn to scale. Q,
polyglutamine region; G, polyglycine region. The different classes of mutation are denoted by colour: turquoise, no significant difference from WT;
blue, loss of function; plum, gain of function upon binding of DHT; orange, loss of function changing to WT values or gain of function upon binding of
DHT; red, constitutive gain of function.
doi:10.1371/journal.pone.0032514.g003
Figure 4. Comparison of the AR-responsive regulatory elements in GRE2-TATA-Luc and PSA61Luc. Note that the second copy of the
HRE in GRE2-TATA-Luc exists as an inverted repeat 29 bp downstream from the first. Nucleotides which differ from the consensus sequences are
shown in bold underlined font.
doi:10.1371/journal.pone.0032514.g004
Impact of Androgen Receptor Mutations
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32514Impact of Androgen Receptor Mutations
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32514In general, the profiles of PSA61Luc stimulation for the
different AR mutations were very similar to those for GRE2-
TATA-Luc; indicating that the findings in the broad GRE2-
TATA-Luc study accurately reveal the effects of the mutations.
Interestingly, the loss of function in the absence of DHT detected
with GRE2-TATA-Luc and AR mutations P390L, T575A and
R629Q was not seen with PSA61Luc. Instead, there was no
significant difference from WT, reflecting probable lower affinity
of unactivated AR for the regulatory elements in the PSA
promoter as evident in the lower basal activity with WT AR. In
vitro studies have demonstrated that the isolated AR-DBD (for
example [69,70]) or AR-NTD-DBD [70] exhibited reduced
affinity for selective androgen response elements (AREs) relative
to hormone response elements, which also bind the glucocorticoid
receptor.
The results for the AR NTD mutations investigated with
PSA61Luc closely matched those for GRE2-TATA-Luc. AR
mutation L57Q had loss of function at all concentrations of DHT
with both reporters although they were less pronounced with
PSA61Luc. Similarly, the profiles of G142V were comparable
with both reporters showing constitutive activity and gain of
function in the presence of DHT. The difference from WT in
upregulation at 1 nM DHT was lower with PSA61Luc than with
GRE2-TATA-Luc and may again be a consequence of weaker
binding between unactivated AR and the androgen-specific AREs
in PSA61Luc. Both P390L and P533S, which represented loss to
gain of function and WT activity to gain of function respectively,
had similar results with the two reporters, albeit with characteristic
lower upregulation at 1 nM DHT. Hyytinen et al noted that P533S
had similar responses to androgens in COS-1 cells using luciferase
reporter plasmids driven by either the rat probasin promoter
(nucleotides 2285 to 32) or two AREs from the first intron of the
rat C3 gene in front of a minimal TATA sequence [71].
Mutations within the DBD and hinge domains of the AR would
be expected to have the greatest influence on regulating ARE
binding and indeed, the profile for T575A in the first zinc finger of
the DBD was markedly different for the two reporters with
PSA61Luc having a loss of function of 15 and 32% at 1 and
10 nM DHT respectively in contrast to gains of 42 and 82% with
GRE2-TATA-Luc. Monge et al have observed that this AR
mutation leads to preferential binding to AR-nonspecific motifs
with concomitant increased transactivation and, conversely, to
reduced transactivation of AR-specific AREs [72]. Of the two
hinge mutations studied, R629Q and I672T, the former exhibited
obvious differences in regulatory element activation. Like most of
the other mutations exhibiting loss of function with GRE2-TATA-
Luc in the absence of hormone, there was no difference from WT
with PSA61Luc. Also, the results at 1 nM DHT showed a gain
and loss of function of 21 and 22% for GRE2-TATA-Luc and
PSA61Luc respectively. Mutation R629Q resides in the C-
terminal extension (CTE) region with the positively charged
629RKLKK
633 motif playing crucial roles in high affinity binding
to AREs, nuclear translocation, nuclear sublocalization, intranu-
clear mobility and transactivation [73]. In addition, post-
translational acetylation of the AR at lysines 630, 632 and 633
fine-tunes the action of AR on target promoters and enhancers.
Glutamine mimics acetylated lysine through similarity in chem-
ical structure and charge, and mutation of K630 to glutamine
produces increased transactivational activity and promotes
prostate cancer cell survival and growth [53]. Therefore, the
consequences in downstream gene regulation of the mutation of
the adjacent R629 to glutamine might arise by interference in
acetylation of the
629RKLKK
633 motif or, conversely, by directly
imitating acetylation of this influential region. On the basis of
homology modeling, I672 resides in a ridge (
670QPIF
673) which,
along with the carboxy-terminal of helix 9, frames a small highly
hydrophobic cleft with the potential to form a protein-protein
interaction surface [29]. Mutation to threonine would disrupt the
conformation, however, no obvious difference from WT transac-
tivational activity was seen with either reporter plasmid in our
studies. This is in contrast to the study cited above which described
a nearly three-fold increase with probasin promoter and MMTV-
driven reporters in PC-3 and CV-1 cells.
The LBD mutations had a greater dependence on the
regulatory elements, emphasizing the importance of interdomain
communication for receptor function. While the major losses of
function seen with M749I at 10 nM DHT were clearly evident
with reductions of 99 and 92% compared to WT with GRE2-
TATA-Luc and PSA61Luc respectively, there was an important
difference in the absence of androgen. With the androgen-specific
regulatory element a low level constitutive activity of 16% was
observed; against a loss of 14%. It has been proposed that specific
loss of function mutations within the LBD including M749I can
confer protection from prostate cancer [74], however, this
mutation has been indentified in combined androgen blockade
relapsed tumors [75] and the constitutive activity may be a
contributing factor. The results for Q798E with GRE2-TATA-Luc
and PSA61Luc were appreciably dissimilar with the modest loss of
function seen with the former reporter (up to 40% at 1 nM DHT)
being transformed to constitutive gains of function of 29, 28 and
17% at 0, 1 and 10 nM DHT respectively with the latter.
Although the values of constitutive transactivation for M749I and
Q798E in the absence of DHT are not exceptionally high, the
occurrence of constitutively active AR signaling could have
profound effects on prostate cancer development over time and
explain, at least in these instances, how mutations with apparent
loss of function can stimulate prostate cancer progression. Lastly,
the PSA61Luc results for H874Y showed increased constitutive
activity with a 64% difference from WT, and the small losses of
function seen at 1 and 10 nM DHT (2 and 15% differences from
WT respectively) became noteworthy gains of function with 123
and 88% increases from WT respectively. Therefore, this
mutation located in helix 10/11 with its constitutive activity on
both AR-specific and –non-specific regulatory elements, and
promiscuous ligand-activation by a wide range of steroid and
nonsteroidal ligands [30,66] represents an especially perfidious
prostate cancer mutation.
Physiological relevance of the mutations
Given that the pathological consequences of AR mutations are
strongly influenced by the concentration of androgens within the
Figure 5. Transactivation activity of mutant ARs on AR-non-specific and AR-specific regulatory elements. COS-7 cells were
cotransfected with either GRE2-TATA-Luc or PSA61Luc reporter plasmid and pSVARo expressing the indicated hAR mutation. After treatment with
DHT, the luciferase activity was determined. The ability of each hAR mutant to upregulate the luciferase reporters was calculated as the fold
stimulation at each concentration of DHT compared to untreated cells transfected with the same luciferase reporter and expressing WT AR. The
results are presented as the percentage difference between the mutant and WT AR at each concentration of DHT, with values below and above zero
representing loss and gain of function compared to WT hAR respectively. Values are means of between three and five independent experiments
performed in quadruplicate 6 SEM.
doi:10.1371/journal.pone.0032514.g005
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interpreting the physiological relevance of the data presented in
this report. Circulating testosterone is produced principally by the
testes with much smaller amounts (about 10%) coming from the
adrenal glands. Both testosterone and DHT, which is produced
from testosterone by the enzyme steroid 5a-reductase (E.C.
1.3.99.5), bind and stimulate the AR, however, the latter has
higher binding affinity and up to 10-fold greater molar potency
[76]. Within the prostate gland, DHT is the dominant androgen
having an approximately 6-fold higher concentration than
testosterone [77]. Steroid 5a-reductase exists as three isoforms:
type 1 is present mainly in hair follicles and skin; type 2 is the main
variant in the prostate and the recently characterized type 3
isozyme is expressed in AI PCa cells [78]. Conversion of
circulating testosterone to DHT is essentially irreversible and
intraprostatic levels of DHT are effectively buffered against
fluctuations in serum testosterone concentrations by the amplifying
action of 5a-reductase [79]. Although serum testosterone levels
can decrease in men over 55 to 60 years old, the activity of 5a-
reductase isozymes remains sufficiently high that DHT levels are
maintained. Studies of serum DHT concentrations in young (19–
35 years old) and older men (59–75 years old) receiving
testosterone therapy while their endogenous hormone production
was suppressed by a gonadotropin-releasing hormone agonist
showed no age-related differences. Production of DHT from
testosterone displayed saturable Michaelis-Menten kinetics and
similar Vmax in both age groups [80].
Intratumoral DHT concentrations can be highly variable and
unrelated to circulating testosterone levels due to alternative
pathways of production and altered amounts of the 5a-reductase
isozymes. PCa cells can convert the blood-borne adrenal steroids
androstenediol and DHEA to testosterone [81,82] which can serve
as a substrate for 5a-reductase. Progression to an AI state and
metastasis is often accompanied by elevated expression of type 1
5a-reductase over type 2. This not only permits increased
conversion of testosterone to DHT, but also allows testosterone
to be bypassed with the enzyme catalyzing the 5a-reduction of
DHEA-derived androstenedione to 5a-androstanedione, which is
then further reduced to DHT [83]. In addition, AI PCa cells can
use progesterone as a precursor for DHT [84], and there is
growing evidence that they may also have the capacity to carry out
de novo androgen synthesis [85]. Type 3 5a-reductase expression
varies with prostate cell malignancy based on immunostaining.
The enzyme is confined to only basal epithelial cells in benign
prostate, whereas in high grade PIN it is found in the characteristic
neoplastic epithelial cells and in PCa at high levels in most
epithelial cells [86].
Several studies on the levels of androgens in prostate biopsies
have been carried out and these have been reviewed by van der
Sluis et al [79]. DHT levels generally ranged between 10.3 and
21.2 nM in patients with benign prostatic hyperplasia and in those
with PCa prior to treatment. Importantly, PCa patients undergo-
ing androgen deprivation therapy (ADT) still had intraprostatic
DHT levels of between 4.6 and 18.7 nM. Therefore, the third and
fourth classes of AR mutation which possess gain of function at
higher concentrations of DHT will retain increased transactiva-
tional activity in elderly men and even in patients receiving ADT.
Mutations with no apparent change of activity from WT may be
able to drive cancer progression though several diverse routes.
These include altered binding to co-repressors or co-regulators e.g.
M886I, regulatory element-dependant outcome, promiscuous
steroid ligand binding, increased half life and raised concentrations
due to gene amplification. Mutations with loss of function can be
deleterious for the same reasons and also because of diminished
action on critical genes downregulated by AR.
Conclusions
This analysis examined 45 single missense mutations detected in
PCa with metastasis or high Gleason scores, and which extend
along the entire length of the protein. Our sensitive assay system
uncovered a previously unidentified category of AR mutation that
possesses loss of function at low levels of DHT; converting to a
gain of function at physiological levels. Importantly, this type of
mutation and virtually all of the other classifications were present
in all the domains of the receptor (Fig. 6). The preponderance of
PCa-associated mutations display loss of function or activity
similar to WT and constitutive gain of function is uncommon.
Also, there was a lack of an obvious relationship between the type
of AR mutation and the severity of the cancer in which it was
detected. Four NTD mutations (G142V, M523V, G524D and
M537V) have constitutive transactivational activity clearly dem-
onstrating that the NTD has bearing on regulatory element
binding; corroborating earlier work showing that intradomain
communication between the NTD and the DBD alters affinity for
different response elements [70]. It is noteworthy that all of these
mutations contain amino acid substitutions capable of forming
intramolecular non-covalent bonds, raising the possibility that
ensuing conformational changes induce their transactivational
properties. The involvement of mutations in all of the other
domains of the AR, not just the DBD e.g. T575A, on regulatory
element binding is unequivocal. This may be of particular medical
relevance as R629Q, M749I and Q798E in the absence of
androgen had loss of function with the hormone response element
in GRE2-TATA-Luc but possessed a constitutive gain of function
with the AREs in the PSA promoter. Therefore, mutations
categorised as having reduced transactivational activity in one
analysis, could well be capable of upregulating prostate cancer-
related genes.
The AR is found in distinct cell types in the prostate e.g. luminal
epithelial cells and stromal cells, including smooth muscle [5,7]
and evidence from mouse models of cell specific AR knock-out
Figure 6. Summary of the distribution of the different classes of mutation along the AR protein.
doi:10.1371/journal.pone.0032514.g006
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tumor suppressor, depending on the cell type [87]. AR ablation
in epithelial cells leads to increased proliferation and a de-
differentiation phenotype [88] while removal of the AR in smooth
muscle cells causes increased hormone-dependent proliferation
[89]. Interestingly, deletion of the AR in both stromal and
epithelial cells reduced proliferation and reduced tumor size in the
TRAMP model [90]. Collectively these results suggest that the
epithelial AR suppresses the growth signals from stromal cells.
Therefore, point mutations in the AR that demonstrate a loss or
gain-of function respectively could be important at different stages
of disease progression, depending on the cell type and when the
mutation occurs.
It is becoming increasingly evident that advanced prostate
cancer tumors consist of multiple colonies of cells containing
different AR mutations, and therapeutic treatment often results in
a culling within the tumor leaving cells with AR mutations
conferring a selective advantage to stage a relapse. A fuller
understanding of the impact of AR mutations will be of clinical, as
well as scientific, value as medical care moves to personalised,
targeted treatment based on the manifestation of specific AR
mutations in biopsies or circulating cancer cells.
Materials and Methods
Cell culture
COS-7 cells [91], an African green monkey kidney cell line,
were obtained from The European Collection of Cell Cultures and
grown in DMEM containing 5 mM Glutamax and 4.5 g/l glucose
(Invitrogen), and supplemented with 10% fetal bovine serum for
maintenance or 10% charcoal-stripped fetal bovine serum (both
from PAA) for treatment with ligand. Cells were maintained at
37uC without antibiotics in a humidified atmosphere containing
95% air and 5% CO2.
Plasmids and site directed mutagenesis
Three different luciferase reporter plasmids were employed:
GRE2-TATA-Luc [92,93]; PSA61Luc [48] and MMTV-Luc [94].
Amino acid substitutions were generated in the full-length human
androgen receptor expression plasmid pSVARo [95] using the
QuikChange II Mutagenesis kit (Agilent Technologies) according
to the manufacturer’s methods. The creation of K720E, H874Y,
T877A and D879G has been described previously [30] and the
other mutations were made with the oligonucleotides and their
complements shown in Table S1. The mutations and integrity of
final products were confirmed by DNA sequencing.
Luciferase reporter gene assays
COS-7 cells were seeded in 24-well plates at a density of
1.25610
4 cells/cm
2 and cultured in complete medium containing
10% charcoal-stripped fetal bovine serum for 24 h. Subsequently,
they were cotransfected with firefly luciferase reporter plasmid and
pSVARo human androgen receptor expression plasmid (150 ng
and 75 ng/well respectively) using jetPEI polyethylenimine trans-
fection reagent (Polyplus Transfection) according to the manufac-
turer’s protocol. After 24 h, the medium was replaced with fresh
charcoal-stripped medium containing either DHT (Sigma) or
solvent vehicle. Twenty four hours later, the medium was aspirated
and the wells washed once with PBS. One hundred and ten micro
litres Passive Lysis Buffer (Promega) were added to each well and
cell lysis was carried out for 15 min with shaking. Cell debris was
removed by centrifugation at 13,000 g for 5 min and lysate
supernatants were used immediately or stored at 280uC.
Luciferase activity was measured in duplicate by adding 10 ml
aliquots of lysate to 96-well plates and using a GloMax 96
Microplate luminometer (Promega) with injection of 100 ml/well
in-house luciferase assay buffer containing 13 mM MgSO47H2O,
30 mM GlyGly pH 7.8, 1.7 mM Na2ATP and 11 mM luciferin
(Invitrogen). The luciferase activities, determined as relative light
units, were normalized for the amounts of expressed androgen
receptor.
Dot blotting
Androgen receptor levels were determined immulogically by dot
blot analysis. Thirty micro litre aliquots of lysate were applied to
Hybond ECL nitrocellulose membrane (GE Health Care Systems)
using a Hybri-Dot vacuum manifold (BRL). After blocking for 1 h
at room temperature in a buffer containing 25 mM Tris–HCl
(pH 7.4), 0.14 M NaCl, 2.7 mM KCl, 0.05% (vol/vol) Tween 20
and 5% (wt/vol) nonfat milk powder, the membrane was
incubated overnight at 4uC in fresh buffer containing 0.2% (wt/
vol) nonfat milk powder and AR441 antibody (sc-7305, SantaCruz
Biotechnology) at a dilution of 1:9,000. The antigen–antibody
complex was detected by incubating the membrane for 1 h at
room temperature in buffer containing 0.2% (wt/vol) nonfat milk
powder and a 1:5,000 dilution of horseradish peroxidase-con-
jugated anti-mouse IgG secondary antibody (Sigma) and visualized
with an in-house blotting substrate containing 100 mM Tris-HCl
pH 7.9, 2.8 mM H2O2, 1.25 mM Luminol (Sigma) and 0.2 mM
p-Coumaric acid.
The amounts of expressed AR were normalized for protein
levels which were determined in 96-well plates using the Bio-Rad
DC Protein Assay (Bio-Rad) with BSA as a standard. Absorption
was measured using a Labsystems Mulitskan MS plate reader and
protein concentrations were calculated using Genesis software
(both Thermo).
Preparation of cell extracts
COS-7 cells were plated in 6-well plates at a density of
1.25610
4 cells/cm
2, cultured in complete medium containing
10% fetal bovine serum for 24 h and transfected with pSVARo
(1 mg/well) using jetPEI. After 24 h, the cells were given fresh
medium and grown for a further 24 h. The wells were washed
with ice-cold PBS and the cells were collected by scraping into ice-
cold PBS followed by centrifugation at 8,000 g for 3 minutes at
4uC. The cell pellets from each well were resuspended in 40 ml ice-
cold lysis buffer containing 100 mM KH2PO4, pH 7.8, 0.2 mM
phenylmethylsulfonyl fluoride and 16 protease inhibitor cocktail
(Roche). Cells were lysed by three cycles of vortexing and freeze/
thaw using liquid nitrogen. Cellular debris was removed by
centrifugation at 14,000 g for 2 minutes at 4uC, and the
supernatants were stored at 280uC.
Western blotting
Samples of 30 mg cell extract were fractionated by SDS-PAGE
with 10% acrylamide gels and transferred onto Hybond-P PVDF
membrane (GE Health Care Systems) by electroblotting. There-
after, the membranes were treated as described for dot blotting
except that the AR441 antibody was used at a dilution of 1:900.
Supporting Information
Table S1 Oligonucleotides (coding strand only) used in creating
single point mutations in the hAR.
(DOC)
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